Tag - GNTA

Developments

Genenta strengthens pact with CDMO to enhance production

Genenta Science (NASDAQ:GNTA) announced that it has amended its development and master services agreement with contract development and manufacturing organization (CDMO) AGC Biologics to bolster production capabilities...

January 10, 2025

Markets

Maxim starts Genenta Science at buy; PT $21

Maxim Group launched coverage of Genenta Science S.p.A (NASDAQ:GNTA) with a “buy” rating and $21 price target. The stock closed at $9.94 on Jan. 12. Genenta is developing cancer therapeutics using an autologous ex...

January 13, 2022

Tag - GNTA

Genenta strengthens pact with CDMO to enhance production

Maxim starts Genenta Science at buy; PT $21

General

More